{"doi":"10.1517/14656566.8.6.839","title":"Tipranavir: a new protease inhibitor for the treatment of antiretroviral-experienced HIV-infected patients","abstract":null,"journal":"Expert Opinion on Pharmacotherapy","year":2007,"id":626146,"datarank":0.47032413238937254,"base_score":3.1354942159291497,"endowment":3.1354942159291497,"self_citation_contribution":0.47032413238937254,"citation_network_contribution":0.0,"self_endowment_contribution":0.47032413238937254,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":22,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1619588,"name":"Judit Morelló","orcid":null,"position":1,"is_corresponding":false},{"id":1619589,"name":"Pilar Garcia-Gascó","orcid":null,"position":2,"is_corresponding":false},{"id":1619591,"name":"Sonia Rodríguez-Novoa","orcid":null,"position":3,"is_corresponding":false},{"id":36911,"name":"Vincent Soriano","orcid":"0000-0002-4624-5199","position":4,"is_corresponding":false},{"id":499025,"name":"Carmen de Mendoza","orcid":"0000-0001-5224-7492","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Tipranavir: a new protease inhibitor for the treatment of antiretroviral-experienced HIV-infected patients","abstract":"Tipranavir (TPV) is a novel non-peptidic protease inhibitor (PI). It binds strongly and selectively to the HIV-1 protease, is orally administered twice daily, boosted with low doses of ritonavir, and shows a favourable resistance profile. In the two registrational trials, named RESIST 1 and 2, TPV/ritonavir 500/200 mg b.i.d., along with an optimised antiretroviral backbone, provided better virologic responses than controls receiving standard of care ritonavir-boosted PI-based regimens. A total of 21 mutations at 16 protease codons have been shown to impact on TPV susceptibility and response rates. The TPV mutation score includes L10V, I13V, K20M/R/V, L33F, E35G, M36I, K43T, M46L, I47V, I54A/M/V, Q58E, H69K, T74P, V82L/T, N83D and I84V. Viruses containing eight or more of these mutations are generally resistant to the drug. TPV use is associated with an excess of grade 3/4 liver enzyme elevations compared with other ritonavir-boosted PIs, and the potential for drug-drug interactions is relevant and must be considered when prescribing TPV.","is_dataset_classified":null,"base_score":3.1354942159291497,"endowment":3.1354942159291497,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"17425479","pmcid":null,"openalex_id":"https://openalex.org/W2030228730","authors":[],"funders":[],"total_grants":0,"fwci":2.6399,"citation_percentile":0.89412279,"influential_citations":0,"citation_trend":[{"year":2012,"count":1},{"year":2016,"count":1},{"year":2025,"count":1}],"oa_status":"closed","license":null,"oa_locations":[{"url":"http://www.tandfonline.com/doi/pdf/10.1517/14656566.8.6.839","host_type":"publisher"},{"url":"https://doi.org/10.1517/14656566.8.6.839","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/17425479","host_type":"repository"}],"fields_of_study":["HIV/AIDS drug development and treatment","HIV Research and Treatment","HIV/AIDS Research and Interventions","Clinical Trials as Topic","Drug Interactions","Drug Resistance, Viral","Drug Therapy, Combination","HIV Infections","HIV Protease","HIV Protease Inhibitors","HIV-1","HIV-2","Humans","Mutation","Pyridines","Pyrones","Ritonavir","Sulfonamides","Treatment Outcome"],"mesh_terms":["Clinical Trials as Topic","Drug Interactions","Drug Therapy, Combination","Humans","Mutation","Pyridines","Pyrones","Sulfonamides","HIV-1","HIV-2","HIV Infections","HIV Protease","Treatment Outcome","HIV Protease Inhibitors","Ritonavir","Drug Resistance, Viral"],"keywords":["Medicine","Protease inhibitor (pharmacology)","Human immunodeficiency virus (HIV)","Virology","Antiretroviral treatment","ANTIRETROVIRAL AGENTS","Antiretroviral therapy","Pharmacology","Viral load"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-04T12:38:46.515720Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}